News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. founder Lisa Conte to present virtually at Emerging Growth Conference on Feb 18, 2025. Company focuses on sustainable pharmaceuticals derived from rainforest plants for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena to submit IND application for psychoactive drug candidate for mental health indications. MB2500 aims to treat cognitive deficit in schizophrenia and ADHD. Magdalena focuses on safe, plant-based drugs under FDA Botanical Guidance -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Sheikh Khalifa Medical City hosts trial for Jaguar's crofelemer, plant-based drug granted Orphan Drug Designation. Study could lead to early patient access in Europe for rare diseases -
